ISPOR EXPANDS SCIENTIFIC STAFF BY ADDITION OF CHIEF SCIENCE OFFICER

Published Sep 1, 2015
Princeton, NJ, USA - The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is pleased to announce it is recruiting for a Senior Director & Chief Science Officer, a new position reporting to the Chief Executive Officer & Executive Director.  This position offers an exceptional opportunity to contribute to the continued success of an internationally recognized health economics and outcomes research society. ISPOR’s knowledge products and services include conferences, education, journals, publications, guidelines, and tools used by thousands of global health economists and health care decision makers annually. By focusing on member input and construction of the consensus view of the appropriate path for advancing HEOR science, the successful candidate will develop, lead, support, and direct strategic initiatives related to research, scientific, and content priorities to accomplish the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. The successful candidate will bring to ISPOR extensive experience.  “We look forward to hearing from senior level candidates with deep professional experience, well versed in health economics and outcomes research as well as a passion for ISPOR.  We encourage applications from the global community based on the following position description”, said Nancy Berg, ISPOR CEO & Executive Director. Further details on the position and application details are available at:  ISPOR eJobs Employment Center.

Related Stories

ISPOR Europe 2026 Plenaries Announced

Sep 30, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced details for its ISPOR Europe 2026 conference. The conference is the leading global event in Europe for health economics and outcomes research (HEOR) and is scheduled for 8-11 November in Vienna, Austria with the theme, “Shaping the Future of Access Through Science and Policy.”

ISPOR and ISPE Publish Joint Real-World Evidence Transparency Position Statement

Sep 29, 2026

Transparency in research enables the public and decision makers to trust the science that underpins real-world evidence (RWE). ISPOR—The Professional Society for Health Economics and Outcomes Research and the International Society for Pharmacoepidemiology (ISPE) have published a joint RWE Transparency Position Statement.

New Study Sheds Light on QALY and Disability Debate

Sep 28, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a study showing no evidence that the use of quality-adjusted life years (QALYs) inherently disadvantages people with disabilities.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×